COST UTILITY AND QUALITY OF LIFE IMPACT OF LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION  by Reddy, Vivek et al.
A353
JACC April 1, 2014
Volume 63, Issue 12
Arrhythmias and Clinical EP
cost utiLity and QuaLity of LifE impact of LEft atriaL appEndagE cLosurE comparEd to 
warfarin for strokE prEVEntion in atriaL fibriLLation
Poster Contributions
Hall C
Saturday, March 29, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Device Management in AF: Devices
Abstract Category: 8. Arrhythmias and Clinical EP: Devices
Presentation Number: 1142-108
Authors: Vivek Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Shannon Armstrong, Colin Taggart, Steve Beard, Chris Knight, David Holmes, Boston 
Scientific, Natick, MA, USA
background:  Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability 
as worse than death. While warfarin is effective at reducing ischemic stroke, it is associated with increased bleeds and lower quality of life (QoL). Left 
atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients, and 
recent data suggest strokes are less disabling. This analysis sought to assess the cost utility of LAAC versus warfarin for stroke prevention in AF.
methods:  A Markov model was constructed from a Medicare perspective comparing clinical outcomes, QoL, and total costs of LAAC versus 
warfarin using PROTECT AF 4-year data. All clinical events reported in PROTECT AF were modeled over 1-year increments to determine time to cost 
effectiveness. New analyses of stroke severity and QoL were incorporated. The model was populated with a cohort of 10,000 70-year old patients 
with a mean CHADS2 score of 2. Cost data were taken from US DRGs.
results:  LAAC was cost effective at 6 years, and dominant (less expensive and more effective) at 10 years. LAAC patients had fewer and less 
disabling strokes and higher QoL, resulting in more QALYs.
conclusions:  Stroke prevention in AF with LAAC provides improved clinical and QoL outcomes, and offers better value to Medicare over a patient’s 
lifetime. This analysis should be considered when formulating policy and practice guidelines.
Results of cost utility analysis of LAAC compared to warfarin at 6 years, 10 years and lifetime
Outcome 6 Years 10 Years Lifetime
Incremental cost per stroke avoided $118,378 Dominant Dominant
Incremental cost per life year gained $40,673 Dominant Dominant
Incremental quality-adjusted life expectancy (impacted by stroke severity) 0.16 years 0.4 years 1.3 years
Incremental cost per quality-adjusted life year (QALY) $37,713 Dominant Dominant
